Discover and read the best of Twitter Threads about #G2P
Most recents (7)
Three doses of vaccine protects healthy people reasonably well against Omicron. The critical question is: how well will vaccines protect the most vulnerable? Here we look at a correlate of vaccine efficacy in a vulnerable group. @TheLancet with @EdjCarr. thelancet.com/journals/lance…
2/n We report authentic live virus neutralisation (best correlate of vaccine efficacy) of Omicron & Delta by haemodialysis (HD) patients after 3rd doses of BNT162b2.
Funding @Kidney_Research @NKF_UK @PKDCharity @KidneyWales
Thanks to patients taking part & @ukkidney colleagues.
Funding @Kidney_Research @NKF_UK @PKDCharity @KidneyWales
Thanks to patients taking part & @ukkidney colleagues.
3/n HD patients had partial protection during Delta wave
VE estimates against hospitalisation of 38% (95% CI 0-57)
medrxiv.org/content/10.110…
@SamiraBell76 @drpaddymark
Of OpenSAFELY co-morbidities, HD had one of the highest death rates
medrxiv.org/content/10.110…
@Roxytonin @OpenSafely
VE estimates against hospitalisation of 38% (95% CI 0-57)
medrxiv.org/content/10.110…
@SamiraBell76 @drpaddymark
Of OpenSAFELY co-morbidities, HD had one of the highest death rates
medrxiv.org/content/10.110…
@Roxytonin @OpenSafely
Why not all doom and gloom? ➡️Broad immune response after 3x vax tackles Omicron in @TheCrick / @UCLHresearch Legacy study of 620 samples from 364 participants. 💡 READ ON... Out @TheLancet, by @MaryYiWeiWu, @dremmacbw, @EdjCarr et al. thelancet.com/journals/lance… 🧵 1/n 
Two doses doesn’t provide nearly as much neutralisation vs. Omicron, especially for Oxford/AstraZeneca recipients. Titres wane, and for 2xPfizer, ~half have no quantifiable neutralisation vs Omicron after 3 months (but nearly all still neutralise Alpha and Delta) 2/n
Differential in Omicron neutralisation after only 2 doses is much clearer when stratifying by those who reported having prior COVID symptoms *plus* 2 doses vaccine. 3/n
I lead the #SIRENStudy and have been studying the impact of prior infection with COVID-19 and COVID-19 vaccinations on immunity for more than 18 months. We have published multiple studies with collaborators. The most recent preprint is available here medrxiv.org/content/10.110… 1/6
In this pre-print, which is under peer review, we demonstrate that 2 doses of vaccination on top of prior of infection, significantly reduces both asymptomatic & symptomatic infection compared to infection alone - Table 3 - the longer since primary infection the more effect 2/6
This is on top of the evidence provided in the original paper showing immunity 81-87% immunity with the original strains and early alpha period.... but just as immunity wanes from vaccines so it does from primary infection. 3/6
pubmed.ncbi.nlm.nih.gov/33844963/
pubmed.ncbi.nlm.nih.gov/33844963/
It's #SARSCoV2 #Omicron time! We have some hopefully significant findings on neutralising antibodies (nAbs) in the 70-89 age group, a group who are at high-risk from #COVID19 medrxiv.org/content/10.110…
The @vGlycoproteins team, including @pizza_regret and @The1stNazerick (joint 1st authors) have looked at neutralisation of >20 different #SARSCoV2 Spike proteins from across the globe🌏🌍🌎!
Sera is from an elderly cohort, vaccinated with Pfizer 3 weeks apart.
Sera is from an elderly cohort, vaccinated with Pfizer 3 weeks apart.
Getting to the last figure first, of course #Omicron. At 3 and 20-weeks post 2nd dose the nAb response to Omicron is pretty much non-existent. However, at 4 weeks post 3rd dose (aka #BoosterJab) all people had detectable neutralising antibodies, which is good news 🙏👍
#eRUPI #UPI Vouchers for benefits is a radical departure from #DBT. Purpose and person aware #G2P payments are here. #SaveOurPrivacy
en.m.wikipedia.org/wiki/Ration_st… is digitized food stamps, but crucial digitization difference is it converts a bearer instrument like stamp / coupon into a person / purpose specific instrument, embedding automatic data emission about beneficiary upon use.
6x reduced antibody neutralisation vs. Delta variant in @TheCrick / @UCLHresearch Legacy study of 106 Oxford-AstraZeneca 1/2-dose vaccinees. 💡Interesting picture emerging, read on! @TheLancet, by @dremmacbw, @MaryYiWeiWu, R Harvey et al. thelancet.com/journals/lance… 1/n
After 1 dose, wide distribution becomes clearer when you ask people if they have had COVID. Suggests Oxford/AZ vaccine is very good at boosting existing immunity, like mRNA: science.sciencemag.org/content/372/65… (So NO antivaxxers, the vaccine doesn’t ‘destroy’ your natural immunity🤦) 2/n
Comparing Oxford/AZ to Pfizer/BioNTech: consistent across variants -- BOTH are generating broad Ab responses, and really good match to real-world vaccine efficacy & models of correlates of protection (2.5x less Ab = ~20% less VE for testing positive)... 3/n
Significant loss of antibody neutralisation vs live B.1.617.2 SARS-CoV-2 variant (-5.8x, akin to B.1.351) in @TheCrick / @UCLHresearch Legacy study of 250 (!) Pfizer-BioNTech 1/2-dose vaccinees, out today @TheLancet, by @dremmacbw, @MaryYiWeiWu et al. thelancet.com/journals/lance… 1/n
Increased age & time since 2nd dose correlated with reduced virus neutralisation across all strains tested. Not a surprise, but given low starting titres vs B.1.617.2, more of a concern to see neutralisation “dropping off”, significantly. Boosters more likely to be needed 2/n
To maximise population coverage, the UK delayed 2nd dose from 3 weeks to ~12 weeks in early 2021. Was a good strategy vs. B.1.1.7, but single-dose vaccine recipients have significantly less ability to neutralise B.1.617.2 -- so strategy now more complicated 3/n
